Oleclumab is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does ...

The revenue for Oleclumab is expected to reach an annual total of $22 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

CD73, an important metabolic and immune escape-promoting gene, catalyzes the hydrolysis of adenosine monophosphate (AMP) to adenosine (ADO). AMP has anti-inflammatory and vascular relaxant properties, ...

Capital structure is the mix of debt and equity that fund a company's operations. A judicious use of debt and equity is a key indicator of a strong balance sheet. A healthy capital structure that ...